comparemela.com

Latest Breaking News On - Hedge funds weigh in on corvus pharmaceuticals - Page 1 : comparemela.com

Insider Buying: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Buys $34,600.00 in Stock

Insider Buying: Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Buys $34,600.00 in Stock
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

William-benton-jones
Securities-exchange-commission
Corvus-pharmaceuticals-stock
Corvus-pharmaceuticals-company-profile
Corvus-pharmaceuticals-inc
Hedge-funds-weigh-in-on-corvus-pharmaceuticals
Nasdaq
Cantor-fitzgerald
Corvus-pharmaceuticals
News-ratings-for-corvus-pharmaceuticals-daily
Get-free-report
Free-report

Corvus Pharmaceuticals (CRVS) Set to Announce Earnings on Tuesday

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) is set to release its earnings data after the market closes on Tuesday, November 7th. Analysts expect Corvus Pharmaceuticals to post earnings of ($0.16) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link. Corvus Pharmaceuticals […]

Hedge-funds-weigh-in-on-corvus-pharmaceuticals
Renaissance-technologies
Corvus-pharmaceuticals-inc
Corvus-pharmaceuticals-price-performance
Earnings-history-for-corvus-pharmaceuticals
Vanguard-group-inc
Cantor-fitzgerald
Corvus-pharmaceuticals-company-profile
Corvus-pharmaceuticals
News-ratings-for-corvus-pharmaceuticals-daily
Blackrock-inc

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Crosses Below 50 Day Moving Average of $2.22

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Crosses Below 50 Day Moving Average of $2.22
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Corvus-pharmaceuticals
Tower-research-capital
Charles-schwab-investment-management-inc
Corvus-pharmaceuticals-price-performance
Corvus-pharmaceuticals-inc
Hedge-funds-weigh-in-on-corvus-pharmaceuticals
News-ratings-for-corvus-pharmaceuticals-daily
Tucker-asset-management
York-mellon-corp
Nasdaq
Cantor-fitzgerald

Short Interest in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Declines By 17.7%

Short Interest in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Declines By 17.7%
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Nasdaq
Vanguard-group-inc
Corvus-pharmaceuticals
Corvus-pharmaceuticals-price-performance
Acadian-asset-management
Corvus-pharmaceuticals-inc
Cantor-fitzgerald
News-ratings-for-corvus-pharmaceuticals-daily
Renaissance-technologies
Hedge-funds-weigh-in-on-corvus-pharmaceuticals
Corvus-pharmaceuticals-company-profile

Corvus Pharmaceuticals (NASDAQ:CRVS) Downgraded by StockNews.com

StockNews.com cut shares of Corvus Pharmaceuticals (NASDAQ:CRVS – Free Report) from a hold rating to a sell rating in a report released on Thursday. Several other research firms have also recently weighed in on CRVS. Cantor Fitzgerald lifted their price objective on Corvus Pharmaceuticals from $2.00 to $4.00 in a report on Tuesday, May 9th. […]

Corvus-pharmaceuticals-stock-performance
Renaissance-technologies
Acadian-asset-management
Corvus-pharmaceuticals-company-profile
Morgan-stanley
Nasdaq
News-ratings-for-corvus-pharmaceuticals-daily
Corvus-pharmaceuticals-inc
Corvus-pharmaceuticals
Vanguard-group-inc
Cantor-fitzgerald

vimarsana © 2020. All Rights Reserved.